Editas Focuses on Developing Eye Candidate EDIT-101

艾尔建与Editas签订合作协议,共同开发莱伯先天性黑蒙症药物EDIT-101

2019-07-09 09:00:00 Zacks

本文共1693个字,阅读需5分钟

On Jul 3, we initiated a research report on Editas Medicine, Inc. EDIT. The company’s lead pipeline candidate, EDIT-101, which uses CRISPR gene editing, is being developed for treating Leber congenital amaurosis type 10 (LCA10), a rare genetic illness that causes blindness. Editas is developing EDIT-101 in partnership with Allergan AGN. The company has a strategic alliance and option agreement with Allergan under which, the latter reserves rights to in-license up to five of Editas’ genome editing ocular programs. Last July, Allergan exercised its option to develop and commercialize EDIT-101 globally while Editas exercised its right to a profit-sharing understanding with Allergan under which, the company will co-develop and equally divide the profits and losses from EDIT-101 in the United States. Both companies plan to begin patient dosing in the phase I/II dose escalation study on EDIT-101 during the second half of 2019. The company is also pursuing the development of CRISPR candidates for eye diseases other than LCA10, which include Usher Syndrome type 2A (USH2A) and the recurrent ocular Herpes Simplex Virus type 1 (HSV-1). Last month, Editas commenced investigational new drug (IND) enabling activities for EDIT-301, an experimental CRISPR medicine, designed to treat sickle cell disease and beta-thalassemia by editing the beta-globin locus. By the end of 2022, Editas targets to have three medicines in early-stage clinical development and at least two in or ready for late-stage studies. Shares of Editas have gained 8% so far this year, underperforming the industry’s rise of 8.3%. We would like to remind investors that genomic editing using CRISPR technology to repair a defective genetic material that causes diseases is probably one of the most promising and exciting healthcare innovations seen in decades. There are only a handful of companies making medicines using this revolutionary technology and Editas is one. The company has two CRISPR platforms, one using the Cas9 protein and the other, the Cpf1 protein. Presently, Editas has no approved product in its portfolio. The company has a couple of high-profile collaborations with big pharma entities for its CRISPR technology, which provide research support and sufficient funds to fulfill its pipeline development plans. Apart from Allergan, it has a collaboration and licensing pact with Juno Therapeutics — now part of Celgene CELG — to use the latter’s gene-editing approaches including CRISPR-Cas9 for developing the engineered T cell medicines to tackle cancer. In April this year, Editas inked a research and cross licensing deal with BlueRock Therapeutics, LP, to combine the respective genome editing and cell-therapy technologies to discover, develop and manufacture novel engineered cell medicines. Due to dearth of a marketed product, Editas is heavily dependent on its partners for collaboration revenues. Apart from EDIT-101, all of Editas’ pipeline candidates are still in the preclinical or research stage of development and will take several years prior to commercialization. Moreover, stiff competition persists as a major concern as other companies, such as CRISPR Therapeutics and Intellia Therapeutics NTLA are either planning to conduct or have already started clinical probes to develop curative CRISPR/Cas9-based medicines. As a result, any regulatory setback in the company’s pipeline development might dent the stock. Editas Medicine, Inc. Price and Consensus Editas Medicine, Inc. price-consensus-chart | Editas Medicine, Inc. Quote Zacks Rank Editas currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Breakout Biotech Stocks with Triple-Digit Profit Potential The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
7月3日,我们发起了一项关于 Editas Medicine , Inc . EDI 的研究报告。 该公司的主要管道候选者 EDI T-101使用 CRISPR 基因编辑,正在研发用于治疗 Leber 先天性黑马病10型( LCA10),一种罕见的导致失明的基因疾病。 Editas 正在与艾尔建(Allergan) AGN 合作开发 EDI-101。该公司与艾尔建(Allergan)签订了战略联盟和期权协议,根据该协议, Allergan 保留对 Editas 最多5个基因组编辑眼程序的授权。Allergan 行使其在全球开发和商业化 EDI T-101的选择权,而 Editas 行使其与艾尔建(Allergan)达成利润分享谅解的权利,据此,公司将共同开发并平均分配来自美国 EDI-101的损益。 两家公司计划在2019年下半年开始进行 EDI-101的 I / II 期剂量递增研究。 公司还在致力于开发除 LCA10以外的其他眼科疾病的 CRISPR 候选者,包括 Usher 综合征2A 型( USH2A )和复发性眼单纯疱疹病毒1型( HSV-1)。 上个月, Editas 开始研究新的药物( IND )使 EDI-301成为一种实验性 CRISPR 药物,旨在通过编辑β-血红蛋白位点来治疗镰状细胞疾病和β-地中海贫血。 到2022年底, Editas 的目标是有三种药物处于早期临床开发阶段,至少有两种正在或准备进行后期研究。 今年以来, Editas 的股价上涨了8%,低于行业8.3%的涨幅。 我们想提醒投资者,利用 CRISPR 技术修复导致疾病的缺陷遗传物质的基因组编辑,可能是几十年来最有希望和最令人兴奋的医疗创新之一。只有少数公司使用这种革命性技术生产药品,而 Editas 就是其中之一。公司拥有两个 CRISPR 平台,一个使用 Cas9蛋白,另一个使用 Cpf1蛋白。 目前, Editas 的产品组合中没有经过批准的产品。该公司与大型制药实体就其 CRISPR 技术进行了几次高调合作,为其提供研究支持和充足的资金以完成其管道开发计划。除了艾尔建(Allergan)之外,该公司还与 Juno Therapeutics (现为新基(Celgene) CELG 的一部分)签订了合作和许可协议,利用后者的基因编辑方法,包括 CRISPR-Cas9开发用于治疗癌症的工程 T 细胞药物。 今年4月, Editas 与 BlueRock Therapeutics , LP 签订了一项研究和交叉许可协议,将各自的基因组编辑和细胞治疗技术结合起来,以发现、开发和制造新型的工程细胞药物。 由于缺乏市场营销产品, Editas 严重依赖其合作伙伴获得合作收入。除了 EDI-101外,所有 Editas 的管道候选项目仍处于开发的临床前或研究阶段,在商业化之前需要几年时间。此外,激烈的竞争仍然是一个主要关切,因为其他公司,如 CRISPR 疗法和 Intellia 疗法 NTLA 正在计划或已经开始进行临床研究,以开发治疗 CRISPR / Cas9为基础的药物。因此,该公司管道开发过程中的任何监管挫折都可能影响该公司的股价。 Editas Medicine , Inc .价格与共识 Editas Medicine , Inc .价格共识图| Editas Medicine , Inc .报价 扎克斯排名 伊迪塔斯目前拥有 Zacks 排名第三(保持)。你可以看到今天的 Zacks #1排名( Strong Buy )股票的完整列表。 三位数利润潜力的生物技术股票 到2024年,随着科学家开发出治疗数千种疾病的方法,生物技术产业预计将突破7750亿美元。他们还找到了编辑人类基因组的方法,从字面上消除我们对这些疾病的脆弱性。Zacks 刚刚发布的世纪生物学:7生物技术股票购买权利现在,以帮助投资者从7个股票盈利准备好跑赢。我们最近的生物技术推荐在短短一个月内就实现了+98%、+119%和+164%的增长。本报告中的股票可能表现更好。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文